In October, we added 134 citations in DIDB, including 51 in vitro (with 29 articles published in October 2022) and 83 in vivo articles (with 40 articles published in October 2022).
Five recently approved NDAs and BLAs were also added: daxibotulinumtoxina (DAXXIFY), deucravacitinib (SOTYKTU), eflapegrastim (ROLVEDON), omidenepag isopropyl (OMLONTI), and terlipressin (TERLIVAZ).
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.